Eric Loumeau - AnaptysBio General Counsel
| ANAB Stock | USD 17.42 0.62 3.44% |
Executive
Mr. Eric Loumeau is General Counsel of the Company. Mr. Loumeau has served as our General Counsel since August 2018. Mr. Loumeau previously served as General Counsel and Chief Compliance Officer of Otonomy, Inc. from May 2015 through March 2018. Before joining Otonomy, Mr. Loumeau served as Chief Financial Officer of Rempex Pharmaceuticals, Inc. from June 2011 to December 2013 and continued as Vice President of Legal Affairs from December 2013 until May 2015 following Rempexs acquisition by The Medicines Company. He also previously functioned as General Counsel at HollisEden Pharmaceuticals, Inc. for over seven years. Mr. Loumeaus experience as outside corporate counsel at national law firms includes tenures at Skadden, Arps, Slate, Meagher Flom LLP, Cooley LLP, Mintz Levin Cohn Ferris Glovsky and Popeo PC, and Bass, Berry Sims PLC since 2018.
| Age | 62 |
| Tenure | 7 years |
| Address | 10770 Wateridge Circle, San Diego, CA, United States, 92121-5801 |
| Phone | 858 362 6295 |
| Web | https://www.anaptysbio.com |
Eric Loumeau Latest Insider Activity
Tracking and analyzing the buying and selling activities of Eric Loumeau against AnaptysBio stock is an integral part of due diligence when investing in AnaptysBio. Eric Loumeau insider activity provides valuable insight into whether AnaptysBio is net buyers or sellers over its current business cycle. Note, AnaptysBio insiders must abide by specific rules, including filing SEC forms every time they buy or sell AnaptysBio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Eric Loumeau over two weeks ago Acquisition by Eric Loumeau of 7288 shares of AnaptysBio subject to Rule 16b-3 | ||
Eric Loumeau over two months ago Acquisition by Eric Loumeau of 29150 shares of AnaptysBio subject to Rule 16b-3 | ||
Eric Loumeau over three months ago Disposition of 5000 shares by Eric Loumeau of AnaptysBio at 14.02 subject to Rule 16b-3 | ||
Eric Loumeau over three months ago Disposition of 3780 shares by Eric Loumeau of AnaptysBio at 38.4103 subject to Rule 16b-3 |
AnaptysBio Management Efficiency
The company has return on total asset (ROA) of (0.1785) % which means that it has lost $0.1785 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6182) %, meaning that it created substantial loss on money invested by shareholders. AnaptysBio's management efficiency ratios could be used to measure how well AnaptysBio manages its routine affairs as well as how well it operates its assets and liabilities. As of January 31, 2025, Return On Tangible Assets is expected to decline to -0.34. In addition to that, Return On Capital Employed is expected to decline to -0.37. At present, AnaptysBio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 11 M, whereas Total Assets are forecasted to decline to about 354.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gayathri Diwakar | Crinetics Pharmaceuticals | N/A | |
| Dana MD | Crinetics Pharmaceuticals | 69 | |
| Kathleen Ford | Kura Oncology | 78 | |
| Mollie MD | Kura Oncology | N/A | |
| Sarah Ryan | Rhythm Pharmaceuticals | N/A | |
| Jennifer Lee | Rhythm Pharmaceuticals | 50 | |
| Francis Burrows | Kura Oncology | N/A | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| Chau MBA | CytomX Therapeutics | N/A | |
| Robert MD | Crinetics Pharmaceuticals | N/A | |
| JD Esq | Kura Oncology | 54 | |
| Jim Flaherty | Rhythm Pharmaceuticals | N/A | |
| Christopher German | Rhythm Pharmaceuticals | 54 | |
| Pete Spain | Kura Oncology | N/A | |
| MS MBA | Kura Oncology | 51 | |
| Alan MD | Crinetics Pharmaceuticals | 62 | |
| Marc CPA | Crinetics Pharmaceuticals | 45 | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Marc Wilson | Crinetics Pharmaceuticals | 45 | |
| Yann Mazabraud | Rhythm Pharmaceuticals | 52 | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.18 |
AnaptysBio Leadership Team
Elected by the shareholders, the AnaptysBio's board of directors comprises two types of representatives: AnaptysBio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AnaptysBio. The board's role is to monitor AnaptysBio's management team and ensure that shareholders' interests are well served. AnaptysBio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AnaptysBio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Martin Dahl, Senior Research | ||
| Monique Silva, Senior Affairs | ||
| James MD, Advisor | ||
| Beth Mueller, Senior Resources | ||
| Priya Raina, Senior Operations | ||
| FAAD MBA, Chief Officer | ||
| Daniel Faga, Interim Director | ||
| MSc MBA, Advisory | ||
| Dennis Mulroy, Chief Officer | ||
| Douglas MBA, Senior CMC | ||
| Eric Loumeau, General Counsel | ||
| Benjamin Stone, Chief Officer | ||
| MSc MD, Senior Development |
AnaptysBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AnaptysBio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (2.90) % | ||||
| Operating Margin | (0.76) % | ||||
| Current Valuation | 116.44 M | ||||
| Shares Outstanding | 30.43 M | ||||
| Shares Owned By Insiders | 1.73 % | ||||
| Shares Owned By Institutions | 98.27 % | ||||
| Number Of Shares Shorted | 6.6 M | ||||
| Price To Earning | 81.21 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.05) | Revenue Per Share | Quarterly Revenue Growth 8.047 | Return On Assets | Return On Equity |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.